A useful biomarker for detecting cardiac amyloidosis (CA) has not been fully established. We aimed to investigate the utility of several biomarkers to detect CA in patients with amyloid light-chain (AL) amyloidosis.
A myloidosis is a group of diseases resulting from extracellular deposition of β-sheet structured amyloid fibril fragments in multiple organs. Cardiac amyloidosis (CA) is the most significant predictor for a poor prognosis in patients with systemic amyloidosis. 1) Among the types of systemic amyloidosis, amyloid lightchain (AL) amyloidosis is caused by deposition of amyloid fibril derived from a misfolded light chain of monoclonal immune globulins generated from abnormal plasma cells. 1) CA in patients with AL amyloidosis who present with symptomatic heart failure (HF) have a median survival of 6 months without successful therapy, 2) because HF in CA patients is generally rapidly progressive and difficult to treat. 2) It is crucial to detect CA at an early stage in order to treat CA or to predict further prognosis of amyloidosis patients. Although endomyocardial biopsy is essentially important to obtain histological evidence of amyloid deposits in the heart, this method is invasive and difficult to perform in CA patients with rapidly progressive HF. Although late gadolinium enhancement in cardiac magnetic resonance is helpful for diagnosing CA, contrast agents cannot be used as renal involvement is common among CA patients. 99m Technetium pyrophosphate (Tc-PYP) cardiac scintigraphy is also available for supporting the diagnosis of cardiac transthyretin amyloidosis, 3) however, this methodology is less effective in patients with AL amyloidosis. 4) Although a variety of cardiac imaging can be utilized for diagnosing CA and predicting the prognosis of CA patients, a simple biomarker which can be measured repeatedly is needed.
Previous studies have reported that several biomarkers, such as high-sensitivity cardiac troponin T (hs-cTnT), 5, 6) N-terminal natriuretic peptide type B (NT-proBNP), 7, 8) and B-type natriuretic peptides (BNP), 9) are potentially useful for predicting prognosis at long-term periods in transthyretin amyloidosis. However, a diagnostic biomarker of CA in AL amyloidosis patients has not yet been fully established. Thus, the aim of this study was to investigate the utility of biomarkers to detect CA in AL amyloidosis patients.
UTILITY OF BNP IN CARDIAC AMYLOIDOSIS

Methods
Subjects and study protocol:
This was a retrospective study in which we reviewed medical records and enrolled patients diagnosed as having AL amyloidosis (n = 63) by histopathological examination between 2008 and 2015 in our hospital. For the diagnosis of AL amyloidosis, serum free light chains were measured, and all patients underwent a biopsy of organs such as the heart, gastrointestinal tract, kidney, lung, and skin, followed by microscopic analysis with Congo red staining and apple-green birefringence examination. To exclude the amyloid A amyloidosis, we examined the signal of the Congo red staining maintained after oxidation with permanganate solution. The diagnosis of AL amyloidosis was confirmed by immunofluorescence staining for the expression of kappa or lambda light chains. The diagnosis was also supported by documented plasma cell dyscrasia (serum M protein or an abnormal free light chain ratio). 10, 11) To screen for cardiac involvement, a 12-lead and/or Holter electrocardiogram (ECG), echocardiography, and laboratory testing were performed in all AL amyloidosis patients, and in case of suspicion of cardiac involvement, additional advanced testing was performed by attending physicians as needed (e.g. scintigraphy, cardiac magnetic resonance, and myocardial biopsy). CA was comprehensively diagnosed based on amyloid deposition in the myocardium, detected by endomyocardial biopsy or autopsy (n = 26) [12] [13] [14] [15] and/or documented fatal arrhythmia accompanied by cardiac abnormal findings proved by echocardiography, electrocardiography, and/or magnetic resonance imaging (n = 4). In some cases (n = 3 in CA patients and n = 1 in non-CA patients), Tc-PYP cardiac scintigraphy was performed to exclude the possibility of ATTR amyloidosis which shows strong uptake of Tc-PYP. The patients were categorized as a non-CA group by the negative findings of cardiac involvement by physiological testing such as electrocardiography and echocardiography, and imaging modalities including late gadolinium enhancement in cardiac magnetic resonance and Tc-PYP cardiac scintigraphy.
We compared the parameters of electrocardiography, echocardiography and several biomarkers, such as BNP, NT-proBNP, hs-cTnT, high-sensitivity cardiac troponin I (hs-cTnI), and serum amyloid A, and the difference between kappa and lambda free light chain (dFLC) between the non-CA (n = 33, 52.4%) and the CA (n = 30, 47.6%) groups. Furthermore, we retrospectively examined allcause mortality after the diagnosis of AL amyloidosis. Data on all-cause mortality were obtained from the patient medical records. Survival time was calculated from the date of amyloidosis diagnosis until the date of death or last follow-up. The study protocol was approved by the Ethics Committee of Fukushima Medical University, and was carried out in accordance with the principles outlined in the Declaration of Helsinki. Reporting of the study conforms to STROBE along with references to STROBE and the broader EQUATOR guidelines. 16) Electrocardiogram and echocardiography: Twelve-lead ECGs were performed using standard equipment and retrospectively reviewed for evidence of heart rate, rhythm, and voltage. The QRS, QT, corrected QT interval (QTc), SV1 voltage, and axis in peripheral leads were analyzed. Low-voltage QRS complexes were defined as QRS amplitude of less than 5 mm in all limb leads. Poor R-wave progression in the precordial leads was defined as no R waves in leads V1 to V3. ST-T change was defined as ST-T elevation or depression by 1 mm or more from the basal line. Furthermore, the presence of right bundle branch block (RBBB), left bundle branch block (LBBB), and left axis deviation was analyzed in all 12-leads. A 24-hour Holter recording was performed under hospitalization. Ventricular premature contraction (VPC) burden (the percentage of VPSs in total beats), non-sustained ventricular tachycardia (NSVT), and atrial fibrillation (AF) were estimated. Frequent VPS was defined as frequency of more than 30 times per hour. NSVT was defined as 3 or more consecutive beats arising below the atrioventricular node, with a mean RR interval of !600 msec and lasting less than 30 seconds. AF included paroxysmal (lasting more than 5 seconds) and persistent AF during Holter monitoring.
Echocardiography was performed blindly by experienced echocardiographers using standard techniques. 17) Echocardiographic parameters such as left ventricular diastolic diameter (LVDd), left ventricular systolic diameter (LVDs), interventricular septum wall thickness (IVS), left ventricular posterior wall thickness (LVPW), left atrium diameter (LAD), early filling (E) and atrial filling (A) velocities, mitral valve annular velocity during early diastole (e'), and tricuspid regurgitation pressure gradient (TRPG) were measured. Left ventricular ejection fraction (LVEF) was calculated using Simpson's method. 14) Left ventricular (LV) mass index was calculated according to the following formula: {0.8 × (1.04[(LVDd + LVPW + IVS) 3 -(LVDd) 3 ]) + 0.6}/ body surface area. 14) Left atrial (LA) volume index was calculated according to the following formula: 0.85 × A1 × A2/L/ body surface area (A1; Max. planimetered LA area in the apical 4-chamber view, A2; Max. planimetered LA area in the apical 2-chamber view, L; Length measured from back wall to line across mitral valve hinge points). 18) The E/A ratio and E/e' ratio were calculated to estimate left ventricular diastolic function. Right ventricular fractional area change (RVFAC), defined as (end diastolic area -end systolic area) end diastolic area × 100, was used as a measure of right ventricular systolic function. All measurements were performed using ultrasound systems (ACUSON Sequoia, Siemens Medical Solutions USA, Inc., Mountain View, CA, USA). Measurement of laboratory data: Blood samples were obtained from all patients at diagnosis. NT-proBNP levels were measured using an electrochemiluminescence immunoassay (Elecsys pro BNP II, Roche Diagnostics Ltd., Rotkreuz, Switzerland), and BNP levels were measured using a specific immunoradiometric assay (Shionoria BNP kit, Shionogi, Osaka, Japan). Hs-cTnT levels were measured using an electrochemiluminescence immunoassay (Elecsys Troponin T hs, Roche Diagnostics Ltd., Rotkreuz, Switzerland). 19) Hs-cTnI levels were measured in EDTA anticoagulated plasma using a refined assay (Abbott-Architect, Abbott Laboratories, Abbott Park, IL, USA). Serum amyloid A levels were measured using a latex aggregation immunoassay (LZ test Eiken SAA kit, KIMISHIMA, ET AL 
Results
The clinical characteristics of the 63 patients are presented in Table I . AL amyloidosis was diagnosed by biopsy of the kidney (46.0%), gastrointestinal tract (41.3%), heart (41.3%), lung (9.5%), and skin (3.2%). Among all of the patients, 30 (47.6%) had CA (CA group) while the remaining 33 (52.4%) did not (non-CA group). In the CA group, 26 patients were diagnosed histologically as cardiac AL amyloidosis by endomyocardial biopsy and/or autopsy, and 1 CA patient out of the 26 patients underwent both endomyocardial biopsy and autopsy. The remaining 4 of the 30 CA patients were diagnosed as CA using imaging modalities comprehensively (e.g. echocardiography, electrocardiography, cardiac magnetic resonance). There were more men in the CA group than in the non-CA group, while age, body mass index, diastolic blood pressure, and the percentage of multiple myeloma or monoclonal gammopathy of undetermined significance UTILITY OF BNP IN CARDIAC AMYLOIDOSIS were comparable between the groups. The systolic blood pressure was significantly lower in the CA group than in the non-CA group. With respect to parameters of electrocardiography (Table II) , the amplitude of SV1 was significantly lower, and the prevalence of low-voltage QRS complexes, ST-T change and ventricular tachycardia were significantly higher in the CA-group than in the non-CA group. In contrast, the axis, QRS duration, QT and QTc interval, and the prevalence of RBBB, LBBB, abnormal Q, poor R progression and AF, did not significantly differ between the groups. Of the echocardiographic parameters (Table II) , LVEF, A wave velocity, and deceleration time were significantly lower, and IVS, LVPW, LAD, E/A, and E/e' were significantly higher in the CA group than in the non-CA group. In contrast, LVDd, LVDs, LV mass index, LA volume index, RVFAC, and prevalence of granular sparkling sign did not significantly differ between the groups. Regarding laboratory data (Table I) , BNP levels were significantly higher in the CA group than in the non-CA group (1200.0 versus 224.0 pg/mL, P < 0.01). In contrast, levels of NT-proBNP, NT-proBNP/BNP ratio, hs-cTnT, hs-cTnI, serum amyloid A, and dFLC did not significantly differ between the two groups. From ROC analysis (Figure 1) , the sensitivity and specificity of BNP (with a cutoff value of 412 pg/mL) were 83% and 70%, respectively, and the area under the ROC was 0.75 (95% CI 0.61-0.90, P < 0.001) in all patients with AL amyloidosis. In contrast, ROC analysis revealed that NT-proBNP, NT-proBNP/BNP ratio, hs-cTnT, hs-cTnI, serum amyloid A, and dFLC were not useful for detecting CA in these AL amyloidosis patients (data not shown).
Furthermore, Kaplan-Meier analysis (Figure 2 , mean 1048 days, range 10-5315 days) showed higher all-cause mortality in the CA group than in the non-CA group (logrank P < 0.001). There were 19 cases of all-cause death in the CA group. The modes of death in the CA group were heart failure (10 cases), sudden death (5 cases), and renal failure (4 cases). In contrast, there were 5 cases of all-cause death in the non-CA group, including pneumonia (3 cases), liver cirrhosis (1 case), and accidental death (1 case). No cardiac death was observed during follow-up in the non-CA group. In Cox proportional hazard analysis, CA was a predictor of mortality in the AL amyloidosis patients (hazard ratio 5.161, 95% confidence interval 1.913-13.920, P = 0.001).
In Cox proportional hazard analysis of biomarkers (Table III) , only BNP, but not NT-proBNP, NT-proBNP/ BNP ratio, hs-cTnT, hs-cTnI, or serum amyloid A was a predictor of all-cause mortality in patients with AL amyloidosis (hazard ratio 3.266, 95% confidence interval 1.498-7.119, P = 0.003). While the systolic blood pressure was significantly lower in the CA group than in the non-CA group, Cox proportional hazard analysis showed that systolic blood pressure was not a predictor of all-cause mortality (data not shown).
Discussion
The present study showed that BNP was a useful biomarker for detecting CA in patients with histologically diagnosed AL amyloidosis. The diagnostic utility of BNP for detecting CA in AL amyloidosis patients may be superior to that of NT-proBNP, hs-cTnT, hs-cTnI, serum amyloid A, or dFLC.
Although cardiac involvement is a leading cause of morbidity and mortality in patients with AL amyloidosis, 3) clinicians often fail to diagnose CA. Myocardial biopsy is invasive and sometimes difficult to perform, thus, CA is generally diagnosed based on a combination of clinical features, including an electrocardiogram, echocardiography, and biomarkers. In the present study, most of the patients in the CA group underwent endomyocardial biopsy and presented higher mortality. Our diagnosis of CA seems to be more precise and reliable compared to those of previous studies. 1, 7, 20) Previous studies showed that electrocardiographic abnormalities such as low-voltage complexes (56%), 21) abnormal Q (44%), poor R progression (44%), 20) and AF UTILITY OF BNP IN CARDIAC AMYLOIDOSIS (20%) 22) were found in most patients with CA. In the present study, histologically diagnosed CA patients presented similar ECG abnormalities; however, their frequency of AF was somewhat low (6.7%). A granular sparkling appearance has been recognized as a typical echocardiographic sign of amyloidosis, although this finding sometimes depends on the gain settings of echocardiographic equipment. 3, 23) In our study, the prevalence of the granular sparkling sign did not differ between the CA patients and non-CA patients. Other abnormalities such as LV thickening and diastolic dysfunction estimated by E/A and E/e' were seen in the CA patients, as reported in previous studies. 8, 20) LV global systolic function is maintained until the late stage of CA (24) . Although LVEF was significantly lower in the CA group than in the non-CA group, the CA patients showed a mean LVEF of 49.3%, suggesting that most of the CA patients had relatively preserved left ventricular systolic function.
With respect to the biomarkers, although it has been reported that the measurement of NT-proBNP, BNP, and cardiac troponins is informative for the diagnosis of CA and risk stratification of AL amyloidosis, 5, 20, 25) we showed here that the diagnostic utility of BNP for detecting CA in patients with AL amyloidosis was superior to NT-proBNP and cardiac troponins. 7) Pre-pro BNP, which consists of 134 amino acids, was synthesized through the transcriptional activation of the Nppb gene. Pre-pro BNP was processed into proBNP (108 amino acids) and subsequently proBNP was cleaved into NT-ProBNP (76 amino acids) and BNP (32 amino acid). 26, 27) NT-proBNP and BNP share a common mechanism of clearance through the glomerulus. In patients with a normal or mildly decreased glomerular filtration rate (GFR), the molar ratio of NT-proBNP to BNP must be 1.0 or less because both peptides are cleared at about the same rate and have similar half-lives. 28) In contrast, the ratio was progressively higher in patients with more severely reduced GFR, suggesting that the influence of renal function on the clearance of NT-proBNP is greater than that on BNP. 28) In the present study, since more than 30% of the patients in either group had low estimated GFR (less than 15 mL/ minute/1.73 m 2 ), it might be possible that the level of NT-proBNP did not differ between the CA and the non-CA groups. Although both BNP and NT-ProBNP were equally used as an excellent biomarker of heart failure, BNP might be superior to cardiac troponins or NT-proBNP for diagnosing CA in patients with AL amyloidosis who often also suffer from renal dysfunction. We determined 412 pg/ mL as the cutoff value of BNP to discriminate between CA and non-CA patients with AL amyloidosis, while the value of 100 pg/mL is generally recognized as a decision threshold of HF patients. 29, 30) Circulating BNP is often affected by several other factors, such as left ventricular hypertrophy, AF, anemia, older age, and renal dysfunction. 29) In this study, both the CA and non-CA groups tended to have LV hypertrophy, anemia, and renal impairment. Thus, it is considered that their cutoff value of BNP was relatively high regardless of the presence or absence of CA. During the development of CA, BNP levels may rise before cardiomyocyte injury enhancement, leading to elevation of cardiac troponins. In this study, the CA patients might have been diagnosed at an earlier stage of HF without ongoing myocardial damage.
On the other hand, it has been reported that elevated serum cardiac troponins and NT-proBNP are useful predictors of overall survival in patients with AL amyloidosis, and a prognostic staging system based on these two biomarkers has been established. 31) dFLC is also a useful predictor. 31) The diagnostic utilities of natriuretic peptide, cardiac troponins, and dFLC in CA are controversial. Since several types of amyloidosis patients have different characteristics in terms of tissue typing, the results of this present study regarding patients with AL amyloidosis could not be generalized to all types of amyloidosis.
Further investigations of biomarkers in the diagnosis and prognosis of CA are needed. Novel biomarkers, such as soluble ST2 32) and Galectin-3, 33) represent different pathophysiological pathways from those of BNP and troponin, and may further improve prognostication in patients with AL amyloidosis. 2) Novel cardiac imaging, such as strain and strain rate imaging derived from speckle tracking in echocardiography, 34) and extracellular volume measurement with cardiac magnetic resonance, 35) may also be useful.
Study limitations:
The current study has several limitations. First, this was a retrospective study of a single center with a relatively small number of patients, so the study may be somewhat underpowered. Regarding the small number of patients in this study, it was unavoidable as CA is a relatively rare disease; however, previous studies enrolled fewer patients than the current study. 1, 20) In the present study, all patients with AL amyloidosis were diagnosed histologically. Although most patients in the CA group were diagnosed histologically based on myocardial biopsy, the patients in the non-CA group did not undergo myocardial biopsy in the current study. Thus, we could not completely deny the underdiagnosis of pathological cardiac amyloidosis in non-CA groups. Further studies with a prospective design and larger population are needed to confirm our findings. Third, we did not consider any changes in parameters, and the baseline data at admission were used for the analyses.
Conclusions
BNP, but not NT-proBNP, hs-cTnT, serum amyloid A, or dFLC, is a useful marker to detect cardiac involvement in AL amyloidosis patients.
